MCRPC
Clinical trials for MCRPC explained in plain language.
Never miss a new study
Get alerted when new MCRPC trials appear
Sign up with your email to follow new studies for MCRPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive therapy shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests a new radioactive drug (lutetium rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose, and to see if it can shrink tumors or lower PSA levels. About 82 …
Matched conditions: MCRPC
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …
Matched conditions: MCRPC
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Matched conditions: MCRPC
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC